| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Lumexa Imaging Holdings, Inc. Common Stock$10.97
-0.08 (-0.72%)
Market Cap
895.74 M
EPS
-
P/E Ratio
-
Value Trade
5.93 M
SEC Financials
Q1 2026Dilution Risk
Revenue
252.54 M
Operating CF
2.93 M
Total Assets
1.76 B
Total Liabilities
1.16 B
Equity
599.62 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
51.23 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
360.88 K
52 Week Range
7.23 - 19.45
% held by Insiders
73.39 %
% held by Institutions
33.29 %
Enterprise Value
1.80 B
Total Shares
95.97 M
Short %
9.77 %
Float Shares
25.82 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LMRI
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
LMRI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-LMRI
Jul 29, 2026▼ -0.7%today
Lumexa Imaging Announces Second Quarter 2026 Earnings Conference Call Date
Lumexa Imaging has announced the date for its second quarter 2026 earnings conference call. The company will release its financial results on August 12, 2026, followed by a live webcast at 5:00 p.m. ET. This event highlights Lumexa's commitment to transparency and communication with stakeholders.
Read more →-LMRI
Jun 2, 2026Lumexa Imaging Announces Joint Venture with Hospital for Special Surgery (HSS) to Expand Advanced Outpatient Imaging in New York
Lumexa Imaging has announced a strategic joint venture with the Hospital for Special Surgery to enhance outpatient imaging services in New York. This partnership marks Lumexa's ninth joint venture and aims to expand access to advanced imaging across the NYC metro area. The collaboration is part of Lumexa's growth strategy to meet increasing demand for outpatient services.
Read more →-LMRI
May 13, 2026▼ -23.3%on this news· ran to -36% by day 3
Lumexa Imaging Announces First Quarter 2026 Results
Lumexa Imaging reported positive first quarter results for 2026, highlighting growth in advanced imaging volumes and the successful establishment of new centers. The company reiterated its full-year guidance, aiming to add 8-10 new locations. CEO Caitlin Zulla emphasized the strong demand and strategic focus on geographic expansion and advanced imaging services.
Read more →-LMRI
May 12, 2026Lumexa Imaging Advances Growth Strategy by Adding Four New Imaging Centers
Lumexa Imaging has announced the addition of four new outpatient imaging centers in 2026, expanding its footprint in the Southeast and Mid-Atlantic regions. This growth includes a joint venture with UPMC in Pennsylvania and reflects the company's ongoing strategy to enhance access to imaging services through partnerships. The expansion aims to capitalize on favorable market trends and maintain a steady growth trajectory.
Read more →-LMRI
May 12, 2026Lumexa Imaging Announces First Quarter 2026 Results
Lumexa Imaging reported its first quarter 2026 results, highlighting a 3.1% increase in consolidated revenues to $252.5 million and a net income of $1.7 million, a significant turnaround from a loss in the previous year. The company reiterated its full-year guidance, expecting revenues between $1.045 to $1.097 billion. CEO Caitlin Zulla emphasized the company's strategic growth plans, including the addition of new imaging centers.
Read more →-LMRI
Apr 28, 2026Lumexa Imaging Announces First Quarter 2026 Earnings Conference Call Date
Lumexa Imaging has announced the release date for its first quarter 2026 financial results, set for May 12, 2026. The company will host a conference call at 5:00 p.m. ET to discuss these results. The audio webcast will be accessible on their Investor Relations website, with a replay available for one year.
Read more →-LMRI
Apr 20, 2026Lumexa Imaging Appoints Kyle Lynch as Chief Growth Officer
Lumexa Imaging has appointed Kyle Lynch as Chief Growth Officer to spearhead its growth strategy. Lynch will focus on expanding the company's platform through joint ventures and acquisitions while enhancing sales productivity. His experience in building business development organizations is expected to drive sustainable growth and improve operational performance. The appointment comes at a time when the outpatient imaging sector is experiencing significant demand.
Read more →-LMRI
Mar 26, 2026▼ -29.8%on this news
Lumexa Imaging Announces Fourth Quarter and Full Year 2025 Results, Reiterates Full Year 2026 Guidance
Lumexa Imaging reported strong financial results for Q4 and full year 2025, with revenues increasing by 7.9% to $267.7 million in the fourth quarter. The company also reiterated its guidance for 2026, expecting revenues between $1.045 to $1.097 billion. Despite a net loss of $28.7 million, the company achieved significant growth in Adjusted EBITDA and reduced leverage, positioning itself for future growth.
Read more →-LMRI
Mar 2, 2026▲ +12.2%on this news
Lumexa Imaging Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Results; Provides 2026 Financial Guidance and Earnings Conference Call Date RALEIGH
Lumexa Imaging has announced its preliminary unaudited financial results for the fourth quarter and full year 2025, indicating strong growth momentum with significant increases in outpatient procedures and advanced imaging services. The company expects at least a 14% growth in Adjusted EBITDA for 2026, bolstered by demand for innovative imaging technologies and new partnerships. The earnings conference call is scheduled for March 26, 2026, to discuss the outcomes and provide guidance for the upcoming year.
Read more →-LMRI
Feb 17, 2026▲ +6%on this news
Lumexa Imaging Announces Participation in Upcoming Investor Conferences
Lumexa Imaging Holdings, Inc. announced its participation in several upcoming investor conferences, including presentations at the Raymond James Institutional Investors Conference and the Barclays Global Healthcare Conference. CEO Caitlin Zulla and CFO Tony Martin will represent the company at these events. The conferences aim to enhance investor engagement and showcase Lumexa's outpatient imaging services.
Read more →-LMRI
Feb 17, 2026▲ +6%on this newsshared move
Lumexa Imaging Announces Participation in Upcoming March 2026 Investor Conferences
Lumexa Imaging Holdings, Inc. has announced that CEO Caitlin Zulla and CFO Tony Martin will participate in upcoming investor conferences. This engagement aims to enhance the company's visibility and strengthen relationships with investors. Lumexa Imaging is a leading provider of outpatient imaging services, operating over 185 centers across 13 states.
Read more →-LMRI
Jan 28, 2026Lumexa Imaging’s Dr. Jennifer L. Kemp Elected to RSNA Board, Advancing National Leadership in Quality and Patient-Centered Care
Dr. Jennifer L. Kemp of Lumexa Imaging has been elected to the RSNA Board, enhancing leadership in radiology. Her role focuses on government relations and advancing patient-centered care. Lumexa Imaging's use of AI technology through Scanslated has significantly improved patient engagement, with high satisfaction reported among users.
Read more →-LMRI
Jan 8, 2026Lumexa Imaging Achieves Record De Novo Expansion in 2025
Lumexa Imaging has achieved a record by opening nine new outpatient imaging centers in 2025, expanding its footprint to over 185 centers across 13 states. The new locations, including centers in South Carolina and North Carolina, enhance access to affordable imaging services. The company aims to continue this growth strategy in 2026, focusing on high-growth metropolitan areas.
Read more →-LMRI
Jan 6, 2026Lumexa Imaging Announces Participation in Upcoming January 2026 Investor Conference
Lumexa Imaging Holdings, Inc. announced its participation in the 44th Annual J.P. Morgan Healthcare Conference. CEO Caitlin Zulla and CFO Tony Martin will present on January 12, 2026, in San Francisco. This event highlights Lumexa's significant role in the outpatient imaging sector, with a large operational footprint across the U.S.
Read more →-LMRI
Dec 12, 2025STOCKHOLDERS AGREEMENT by and among LUMEXA IMAGING HOLDINGS, INC. and THE ENTITIES NAMED IN THE PREAMBLE Dated as of
Lumexa Imaging Holdings, Inc. has entered into a Stockholders Agreement with several affiliated entities as it prepares for a potential initial public offering (IPO). This agreement, effective from December 12, 2025, outlines the governance structure and various operational provisions intended to enhance the management and oversight of the company. The parties aim to clarify their respective roles and responsibilities following the IPO's completion. The document suggests a strategic move towards enhancing stakeholder understanding and compliance as the company advances towards public trading.
Read more →-LMRI
Dec 10, 2025Lumexa Imaging Announces Pricing of Initial Public Offering
Lumexa Imaging Holdings, Inc. has priced its initial public offering at $18.50 per share, offering 25 million shares. The IPO is set to begin trading on the Nasdaq under the ticker 'LMRI' on December 11, 2025. The company has also granted underwriters a 30-day option to purchase additional shares. The offering is expected to close on December 12, 2025, subject to customary conditions.
Read more →-LMRI
Dec 2, 2025Lumexa Imaging Announces Launch of Initial Public Offering
Lumexa Imaging Holdings, Inc. has announced the launch of its initial public offering, offering 25 million shares priced between $17.00 and $20.00. The company has granted underwriters a 30-day option for an additional 3.75 million shares. The stock will be listed on the Nasdaq Global Market under the ticker 'LMRI'. Major financial firms are involved in the offering.
Read more →-LMRI
Aug 4, 2025Lumexa Imaging Names Radiologist Dr. Russell Stewart as Chief Medical Officer
Lumexa Imaging has appointed Dr. Russell Stewart as its new Chief Medical Officer. Dr. Stewart, a board-certified musculoskeletal radiologist, has a strong background in clinical radiology and healthcare innovation. He previously served as Chief Clinical Officer at Covera Health and has held leadership roles at Stanford University Medical Center. His role will focus on enhancing quality and patient safety while advancing technology-driven solutions.
Read more →-LMRI
Jul 8, 2025US Radiology Specialists Rebrands as Lumexa Imaging, Ushering in a New Era of Growth and Transformation
US Radiology Specialists has rebranded as Lumexa Imaging, reflecting its commitment to enhancing outpatient imaging services. The company operates over 180 centers across 13 states and aims to meet the growing demand for accessible and cost-effective imaging alternatives. The rebranding is part of a broader strategy to expand its footprint and improve patient experiences.
Read more →-LMRI
Apr 30, 2025US Radiology Specialists Opens Eighth New Imaging Center in Past Seven Months
US Radiology Specialists has opened its eighth new imaging center in Waco, TX, since October 2024, continuing its expansion strategy. The company plans to open a total of 12 new centers in 2025, enhancing access to outpatient imaging services. CEO Caitlin Zulla emphasized the importance of bringing services to underserved areas, aiming to improve patient care.
Read more →-LMRI
Jan 7, 2025US Radiology Specialists Names Experienced Healthcare Executive Caitlin Zulla as New Chief Executive Officer
US Radiology Specialists has appointed Caitlin Zulla as its new CEO, succeeding Lee Cooper. Zulla has a strong background in healthcare leadership, previously serving as CEO of Optum Health East and SCA Health. She aims to enhance the organization's outpatient imaging services and improve patient care. Lee Cooper will continue as Board Chair, supporting Zulla's leadership.
Read more →-LMRI
Oct 10, 2024US Radiology Specialists Launches Next Phase of Its Technologist Advancement Academy with Expansion Into Mammography
US Radiology Specialists has announced the expansion of its Technologist Advancement Academy (TAA) into mammography, enhancing training for imaging technologists. The program aims to address the nationwide shortage of imaging professionals while providing career pathways for employees. Key achievements include the graduation of 19 technologists and ongoing training for 27 others in MRI and CT. The initiative reflects the company's commitment to professional development and improved patient care.
Read more →-LMRI
Jul 29, 2024iCAD and Windsong Radiology Announce Strategic Commercial Agreement to Implement AI-Powered Mammography
iCAD, Inc. has entered a strategic agreement with Windsong Radiology Group to implement its ProFound AI Breast Health Suite across Windsong's locations. This AI-powered technology aims to enhance mammography readings, improving early breast cancer detection while reducing false positives. The collaboration reflects a commitment to advancing patient care through innovative imaging solutions.
Read more →-LMRI
Mar 21, 2024US Radiology Specialists Announces New Chief Executive Officer & Board Chair
US Radiology Specialists has appointed Lee Cooper as the new CEO and Molly Joseph as the Board Chair, effective April 1, 2024. Cooper, with nearly 30 years at GE, aims to continue the company's growth and commitment to high-quality patient care. Joseph brings significant governance experience from her previous role at UnitedHealthcare Global.
Read more →-LMRI
Nov 9, 2023US Radiology Specialists Featured on Triangle Business Journal’s Annual List of Fastest-Growing Companies for Fourth Consecutive Year
US Radiology Specialists has been named one of the fastest-growing private companies in the Raleigh region for the fourth consecutive year by the Triangle Business Journal. This recognition highlights the company's substantial growth and commitment to providing quality diagnostic imaging services. The CEO emphasized the importance of their workforce and the favorable business environment in Raleigh for their continued success.
Read more →-LMRI
Oct 18, 2023US Radiology Expands Use of SCANSLATED AI-Powered Patient Reporting to More Than 110 Outpatient Centers Nationwide; 95 Percent of Patients Report Improved Understanding of Imaging Results
US Radiology Specialists has expanded the SCANSLATED AI-powered patient reporting system to over 110 outpatient centers across the U.S. This platform simplifies complex radiology terminology, resulting in improved patient understanding of imaging results. Feedback indicates that 95% of patients found the new format helpful, enhancing their interactions with healthcare providers.
Read more →-LMRI
Aug 28, 2023US Radiology Specialists Named One of the Best Places to Work
US Radiology Specialists has been awarded the 2023 Best Places to Work by the Triangle Business Journal, highlighting its commitment to employee satisfaction and community service. The award reflects high employee ratings in teamwork, trust, and manager effectiveness. Additionally, the company has been recognized for its diversity and inclusion programs, as well as its competitive compensation and benefits.
Read more →-LMRI
Aug 15, 2023Recruiting Begins for US Radiology Connexia: A Next Generation Teleradiology Organization Focused on Flexibility, Quality, and Connectivity
US Radiology Specialists has begun recruiting for US Radiology Connexia, a new teleradiology organization aimed at providing flexible work options for radiologists. The initiative addresses the rising demand for outpatient imaging while catering to the evolving needs of radiologists seeking work-life balance. Connexia emphasizes clinical quality and peer connectivity, positioning itself as a leader in the teleradiology sector.
Read more →Competitive Position
How LMRI ranks across every disease it competes inCompetitive Position is a premium feature
See how LMRI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial